The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist.
Dopexamine increases inotropic state and rate of relaxation independent of changes in heart rate. Dopexamine has a chronotropic effect and results in a decrease in systemic vascular resistance. Dopexamine has a spectrum of action that should be useful in patients with severe heart failure.
Jaski
B E
BE
Wijns
W
W
Foulds
R
R
Serruys
P W
PW
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004298:Dopamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D011954:Receptors, Dopamine; C046318:dopexamine; D004298:Dopamine